Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6229 in critically ill sepsis patients
NCT05208112Phase 1Completed
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of isupartob sodium in sepsis and septic shock. Primary endpoints: Activated Partial Thromboplastin Time changes at 72 hours and Peak plasma concentration at 72 hours. Started Apr 2022; status: completed.
02
Drugs
isupartob sodium
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT05208112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208112.